ANAHEIM, CA , Jan. 26, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that it held a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) on January 24, 2018 regarding the Company's naltrexone implant, BICX102. BICX102 is the Company's sustained release naltrexone implant for the treatment of opioid and alcohol use disorders.
The National Institute on Drug Abuse (NIDA) joined the meeting as observers, along with Brady Granier, CEO and Director of BioCorRx, and the Company’s regulatory experts and consultants. In the meeting, BioCorRx discussed the responses that were received prior to the meeting from the FDA in regard to the pre-IND package, which had been submitted last month. The package included information on BICX102, as well as the proposed development plan for commercialization. As a result of the meeting, the Company plans to move forward with the product as anticipated.
Brady Granier, President, CEO and Director of BioCorRx, stated, “We are pleased with the FDA’s responses to our development plan and appreciative of their time in the meeting. We look forward to providing a more thorough update as soon as we receive and review the meeting minutes from the FDA as to confirm all items verbally discussed. In the meantime, we will continue moving forward with our BICX102 plans.”
News 
Market Data 
Discover 
AI
